Updating the prostate cancer risk indicator for contemporary biopsy schemes

Canadian Journal of Urology

Volumn 18, Issue 2, 2011, Pages 5625-5629

  Bul, Meelan ^a   Delongchamps, Nicolas B ^b   Steyerberg, Ewout W ^a   De La Roza, Gustavo ^c   Van Leeuwen, Pim J ^a   Zhu, Xiaoye ^a   Van Vugt, Heidi A ^a   Haas, Gabriel P ^d   Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b université Paris Cité   (France)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Early detection; Needle biopsy; Nomograms; Prostatic neoplasms

Indexed keywords

AGED; ARTICLE; CADAVER; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; NOMOGRAM; PATHOLOGY; PROBABILITY; PROSTATE; PROSTATE TUMOR; RISK FACTOR;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CADAVER; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PROBABILITY; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80053350705     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328.
2. Roobol MJ, Kerkhof M, Schroder FH et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009;56(4):584-591.
3. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-1319.
4. Crawford ED, Grubb R 3rd, Black A et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011;29(4):355-361.
5. Roemeling S, Roobol MJ, De Vries SH et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 2007;51(5):1244-1250; discussion 1251.
6. Van Den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55(1):1-8.
7. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17):2095-2101.
8. Penson DF, Mclerran D, Feng Z et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008;179(5 Suppl):S40-S44.
9. Fransson P. Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer--15 years' follow-up. A comparison with age-matched controls. Acta Oncol 2008;47(5):852-861.
10. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-878.
11. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170(5):1792-1797.
12. Steyerberg EW, Roobol MJ, Kattan MW, Van Der Kwast TH, De Koning HJ, Schroder FH. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007;177(1):107-112.
13. Haas GP, Delongchamps NB, Jones RF et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007;99(19):1484-1489.
14. Delongchamps NB, De La Roza G, Jones R, Jumbelic M, Haas GP. Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int 2009;103(1):49-54.
15. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29(9):1228-1242.
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59(4):225-249.
17. Ferlay J, Parkin DM, Steliarova-foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-781.
18. Dong F, Kattan MW, Steyerberg EW et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008;180(1):150-154; discussion 154.
19. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52(5):1309-1322.
20. Scattoni V, Raber M, Abdollah F et al. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 2010;57(1):1-8.
21. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009;73(5 Suppl):S4-S10.
22. Schroder FH, Van Den Bergh RC, Wolters T et al. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010;57(2):256-266.
23. Van Den Bergh RC, Vasarainen H, Van Der Poel HG et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 2010;105(7):956-962.